Skip to main content

Chu Yu-Waye

In the past year, 1 open-market sale filing worth $136.6K and no purchases.

Current role at each company

Open-market trades in the past year

Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.

Bought
–
0 filings
Sold
$136.6K
1 filing
Net
−$136.6K
Bought minus sold
Companies
1
With open-market trades

Trades

Every Form 4 that lists Chu Yu-Waye as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

CTMX CytomX Therapeutics, Inc.

Chief Medical Officer2 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 19, 2026 (view filing)Mar 172 daysChu Yu-WayeChief Medical OfficerSSale−21.3K$6.42−$136.6K−10.1%189.4K after
Mar 20, 2025 (view filing)Mar 182 daysChu Yu-WayeChief Medical OfficerSSale−4.03K$0.60−$2.42K−2.9%135.7K after

FATE Fate Therapeutics Inc

Chief Medical Officer5 trades

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 19, 2023 (view filing)Apr 181 dayChu Yu-WayeChief Medical OfficerSSale−2.53K$6.57−$16.6K−1.8%140.7K after2 lots10b5-1
Jan 11, 2023 (view filing)Jan 101 dayChu Yu-WayeChief Medical OfficerSSale−7.83K$5.24−$41.0K−5.2%143.2K after
Apr 21, 2022 (view filing)Apr 192 daysChu Yu-WayeChief Medical OfficerSSale−4.06K$35.37−$143.7K−2.6%151.0K after
Jan 13, 2022 (view filing)Jan 112 daysChu Yu-WayeSenior VP Clinical DevelopmentSSale−3.96K$48.51−$192.3K−3.2%121.8K after2 lots
Dec 13, 2021 (view filing)Dec 103 daysChu Yu-WayeSenior VP Clinical DevelopmentSSale−7.50K$51.46−$385.9K−5.6%125.8K after7 lots